Megan Leslie and Julian Mulia, co-founders of NanoTess, creators of NanoSALV NanoTess
Megan Leslie and Julian Mulia, co-founders of NanoTess, creators of NanoSALV NanoTess W21C Research and Innovation Centre generates evidence to show feasibility and impact of NanoSALV's cutting-edge product Chronic wounds can delay recovery, increase pain and heighten the risk for serious infection for people in hospital or other health-care settings. For that reason, a Calgary company has developed an innovative gel technology found to be more effective than current wound dressings in helping to heal chronic wounds. Better healing can improve quality of life, lessen the risk of complications, and decrease an individual's reliance on the health-care system. The potential impact is significant, with a recent audit showing one in six patients having a pressure injury (just one type of chronic wound), after being admitted to a Calgary hospital. NanoTess created NanoSALV Catalytic Advanced Wound Care Treatment Matrix, a gel that uses proprietary nanotechnology. NanoSALV seeks to maximize natural wound healing while providing infection protection against pathogens. Alberta Health Services' (AHS) Innovation and Business Intelligence (IBI) team, in collaboration with the CAN Health Network, partnered with W21C Research and Innovation Centre to conduct a real-world evaluation of NanoSALV's implementation feasibility, clinical effectiveness, and impact on patients, their caregivers and health providers. "W21C offers companies like NanoSALV, who are bringing new health solutions to market, an opportunity to validate the technology within a real-world environment," says NanoTess co-founder Julian Mulia.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
